Eaton's Innovative Safety Solutions Help Accelerate Electrified Vehicle Transition
11.6.2024 13:30:00 EEST | Business Wire | Press release
Intelligent power management company Eaton today announced its comprehensive suite of safety-focused electrified vehicle (EV) technologies will be on display June 18-20 in Hall 10-A36 at The Battery Show Europe in Stuttgart, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611322422/en/
Eaton plans to show its suite of safety-focused electrified vehicle (EV) technologies June 18-20 at The Battery Show Europe in Stuttgart, Germany. (Photo: Business Wire)
“While EV adoption continues to increase, we are helping our global customers meet the growing demand with innovative new technologies,” said Mark Schneider, president, Eaton’s eMobility business. “Safety is always a priority, whether the vehicle is powered by gasoline or electricity, and our EV solutions ensure occupants and the vehicle itself remain secure.”
Breaktor a pioneering high-voltage EV protection device
Eaton’s Breaktor® circuit protection technology combines the function of fuses, pyro switches, and contactors into a single coordinated and resettable device. As electric vehicle power levels increase, Breaktor solves the ever-increasing coordination challenge between fuses and contactors and offers extremely fast, safe and reliable protection for high-power battery and inverter systems.
3-in-1 battery vent valve improves battery pack leak testing
Eaton’s 3-in-1 battery vent valve is the first-to-market solution that is capable of three unique functions. In addition to passive and active venting, to provide overpressure relief for the vehicle’s battery pack, it includes an industry first battery-case leak-check mechanism.
It can open up during testing, allowing battery makers to completely leak-check the fully assembled battery pack with the valve in place. This provides customers with the peace of mind that all sealing surfaces of the battery pack are fully tested against water ingress. This Eaton-developed technology improves the safety of vehicles during normal operation and in the event of flooding situations.
The vent valve is precisely and flexibly designed to meet specific opening pressures and optimize venting. Its spring-based actuation technology allows Eaton to accommodate different opening pressure requirements with the same valve design to drive economies of scale.
Fuel tank isolation valve releases pressure in hybrid-electric vehicles
Eaton’s next-generation fuel tank isolation valve (FTIV) releases pressure in the gas tank of a hybrid-electric vehicle since the gas engine in a hybrid vehicle does not operate continuously. Pressure has to be released when the vehicle is in electric mode, and when refueling it’s important the tank is depressurized to avoid spit back.
High Power Lock Box terminals provide protection against the elements
Eaton’s High Power Lock Box (HPLB) terminals, which serve as the interface to a conductor and create a point where external circuits can be connected, are ideal for current and future EV solutions. They have numerous benefits over competitive solutions, including a space-saving profile, superior performance, cost savings, and reduced manufacturing complexity. They also provide efficiency, reliability and protection against the elements.
Eaton Bussmann series fuses optimized for high-powered electrified vehicles
Eaton Bussmann® series fuses feature ratings of up to 1,000 volts of direct current (VDC) and up to 600 amps, enabling them to meet the requirements for use in high-powered EVs.
Eaton's hybrid and EV fuses are designed to manage and protect the charging systems of electric commercial, passenger and high-performance vehicles such as sports cars and large sport-utility vehicles.
Learn more about Eaton’s EV solutions.
Eaton is an intelligent power management company dedicated to protecting the environment and improving the quality of life for people everywhere. We make products for the data center, utility, industrial, commercial, machine building, residential, aerospace, and mobility markets. We are guided by our commitment to do business right, to operate sustainably, and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy sources, helping to solve the world’s most urgent power management challenges, and building a more sustainable society for people today and generations to come.
Eaton was founded in 1911 and has been listed on the New York Stock Exchange for more than a century. We reported revenues of $23.2 billion in 2023 and serve customers in more than 160 countries. For more information, visit www.eaton.com. Follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611322422/en/
Contacts
Thomas Nellenbach
thomasjnellenbach@eaton.com
(216) 333-2876 (cell)
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom